Sanofi’s Efdoralprin Alfa Gains EMA Orphan Status for Rare Lung Disease 
Citi Appoints Ryan Ellis as Head of Markets Sales for Australia and New Zealand 
FedEx Beats Q2 Earnings Expectations, Raises Full-Year Outlook Despite Stock Dip 
Amazon in Talks to Invest $10 Billion in OpenAI as AI Firm Eyes $1 Trillion IPO Valuation 
TikTok U.S. Deal Advances as ByteDance Signs Binding Joint Venture Agreement 
Robinhood Expands Sports Event Contracts With Player Performance Wagers 
Maersk Vessel Successfully Transits Red Sea After Nearly Two Years Amid Ongoing Security Concerns 
Blackstone Leads $400 Million Funding Round in Cyera at $9 Billion Valuation 
MetaX IPO Soars as China’s AI Chip Stocks Ignite Investor Frenzy 
Oracle Stock Surges After Hours on TikTok Deal Optimism and OpenAI Fundraising Buzz 
LG Energy Solution Shares Slide After Ford Cancels EV Battery Supply Deal 
Union-Aligned Investors Question Amazon, Walmart and Alphabet on Trump Immigration Policies 
ANZ New CEO Forgoes Bonus After Shareholders Reject Executive Pay Report 
Oracle Stock Slides After Blue Owl Exit Report, Company Says Michigan Data Center Talks Remain on Track 
Shell M&A Chief Exits After BP Takeover Proposal Rejected 
Elliott Management Takes $1 Billion Stake in Lululemon, Pushes for Leadership Change 
EMERYVILLE, Calif., Sept. 20, 2016 -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of orphan and central nervous system (CNS) disorders, today announced that Stephen J. Farr, Ph.D., President and CEO, will present a corporate update at the Ladenburg Thalmann 2016 Healthcare Conference, and will participate in a fireside chat at the LEERINK Partners Rare Disease & Immuno-Oncology Roundtable Series.
Ladenburg Thalmann 2016 Healthcare Conference -- Zogenix Presentation Details
| Date: | Tuesday, September 27, 2016 | |||
| Time: | 4:00 pm Eastern Time / 1:00 pm Pacific Time | |||
| Location: | New York, NY | |||
LEERINK Partners Roundtable Series: Rare Disease & Immuno-Oncology -- Zogenix Presentation Details
| Date: | Wednesday, September 28, 2016 | |||||
| Time: | 10:00 am Eastern Time / 7:00 am Pacific Time | |||||
| Location: | New York, NY | |||||
The presentations will be webcast live and can be accessed on Zogenix's Investor Relations website at ir.zogenix.com.
About Zogenix
Zogenix, Inc. (Nasdaq:ZGNX) is a pharmaceutical company committed to developing and commercializing CNS therapies that address specific clinical needs for people living with orphan and other CNS disorders who need innovative treatment alternatives to improve their daily functioning.
For more information, visit www.zogenix.com.
CONTACT: Investors: Andrew McDonald Founding Partner, LifeSci Advisors LLC 646-597-6987 | [email protected]
